Compare BridgeBio Pharma Inc (BBIO) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Marathon Digital Holdings Inc — how do they compare? BridgeBio Pharma Inc trades at $82.56 (market cap $16.46B), while Marathon Digital Holdings Inc trades at $11.89 (market cap $4.64B). The key difference: BridgeBio Pharma Inc is far larger — about 3.5× Marathon Digital Holdings Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | MARA | |
|---|---|---|
Market Cap | $16.46B | $4.64B |
Sector | Health | Technology |
52-Week High | $90.17 | $22.84 |
52-Week Low | $44.81 | $6.73 |
Enterprise Value | $18.02B | $6.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
MARA Holdings trades at $12.19, down 3.25% in the last session. The stock faces bearish technical signals and has missed earnings estimates for three consecutive quarters, with a net income margin of -234.83% in 2025. Recent news highlights the company's strategic pivot to AI infrastructure, including a Texas land acquisition adding 2 GW of power capacity, positioning it for potential growth in high-performance computing.
The outlook is mixed: analyst consensus is a Buy with a $17.88 price target, but significant execution risks exist amid persistent losses and high cash burn. Investors must weigh the AI pivot's long-term potential against near-term financial instability and competitive pressures in the evolving digital infrastructure market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
